Promising Prostate Cancer Therapy
The theranostic agent 67Cu-SAR-bisPSMA advances in trials, offering a promising, targeted treatment option for metastatic castration-resistant prostate cancer with limited existing therapies.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.